

# Intervention for medication management in kidney transplant recipients

<b>Submission date</b> 03/04/2024	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 13/05/2024	<b>Overall study status</b> Ongoing	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 09/07/2025	<b>Condition category</b> Urological and Genital Diseases	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

Kidney transplantation is the best and most cost-effective treatment for end-stage kidney disease. Kidney transplant recipients are required to take lifelong immunosuppression medication (ISM) to prevent the body from rejecting the transplanted kidney. However, up to 60% of patients report not taking ISM as prescribed. It is necessary to develop evidence-based interventions to support patients with medication self-management and the challenges associated with taking ISM, to ensure successful patient and transplant outcomes. This study aims to develop and assess the feasibility and acceptability of a self-directed psycho-educational intervention booklet to support ISM taking in kidney transplant recipients. The study consists of two phases. Phase 1 will inform intervention development by improving our understanding of kidney patients' lived experiences of taking medication. Phase 2 aims to assess the feasibility and acceptability of the intervention from both patient and healthcare professional perspectives.

### Who can participate?

Phase 1: Adults living with kidney disease. Participants must be able to speak and understand English. Participants cannot be under the care of a psychiatrist for a mental health condition. Phase 2: Adults living with a kidney transplant, who have been prescribed immunosuppression medication and experience challenges with medication taking. Participants must be able to read and speak English. Participants cannot be under the care of a psychiatrist for a mental health condition. Healthcare professional participants will be those involved in kidney transplant recipient care, i.e. consultant nephrologists, specialist renal transplant nurses, renal pharmacists and renal psychologists.

### What does the study involve?

Phase 1: Patients living with kidney disease will complete a one-to-one semi-structured interview with a member of the research team to discuss their experiences of taking medication, including any motivations or barriers surrounding medication taking. Phase 2: Kidney transplant recipients will be sent a self-directed psycho-educational intervention booklet to work through. Before and after the intervention, participants will complete questionnaires assessing medication-taking behaviour, distress, quality of life, illness perceptions, medication beliefs and satisfaction with information about treatment. Participants

may also take part in an interview to share their experiences of the intervention. Healthcare professionals involved in kidney transplant recipient care will be given the intervention booklet to review. Following this, they will complete a survey and optional interview to explore their thoughts and opinions of the intervention.

What are the possible benefits and risks of participating?

Results of Phase 1 will improve knowledge of lived experiences of taking medication as a kidney patient and inform the tailoring of the intervention to this population. All Phase 2 participants will receive an intervention that will potentially improve medication self-management. Participation will help inform future research to support medication management in kidney transplant recipients.

Phase 1 participants may find discussing experiences of living with a kidney transplant and taking medication distressing. Phase 2 participation will require some time commitment to work through self-guided material. Although unlikely, it is possible that completing Phase 2 questionnaires may cause some distress.

Where is the study run from?

The day-to-day running and management of the project will be carried out in the academic offices of the Immunoregulation Laboratory (Guy's Hospital) and the Health Psychology Department, King's College London (Guy's Hospital). Recruitment will be conducted at Guy's Hospital Kidney Clinic.

When is the study starting and how long is it expected to run for?

June 2021 to June 2025

Who is funding the study?

Kidney Research UK (KRUK)

Who is the main contact?

1. Dr Lyndsay Hughes, [lyndsay.hughes@kcl.ac.uk](mailto:lyndsay.hughes@kcl.ac.uk)
2. Dr Antonia Cronin, [antonia.cronin@gstt.nhs.uk](mailto:antonia.cronin@gstt.nhs.uk)

## Contact information

### Type(s)

Scientific

### Contact name

Ms Rosie Heape

### Contact details

5th Floor Southwark Wing  
Guy's Hospital  
London Bridge  
London  
United Kingdom  
SE1 9RT

-  
[rosie.heape@kcl.ac.uk](mailto:rosie.heape@kcl.ac.uk)

### Type(s)

Principal Investigator

**Contact name**

Dr Antonia Cronin

**ORCID ID**

<https://orcid.org/0000-0003-4631-0787>

**Contact details**

5th Floor, Southwark Wing  
Guy's Hospital  
London  
United Kingdom  
SE1 9RT  
+44 (0)7741286493  
[antonia.cronin@gstt.nhs.uk](mailto:antonia.cronin@gstt.nhs.uk)

**Type(s)**

Principal Investigator

**Contact name**

Dr Lyndsay Hughes

**ORCID ID**

<https://orcid.org/0000-0003-4907-0168>

**Contact details**

Health Psychology Section (IoPPN)  
King's College London  
5th Floor Bermondsey Wing  
Guy's Hospital  
London  
United Kingdom  
SE1 9RT  
+44 (0)2071889779  
[lyndsay.hughes@kcl.ac.uk](mailto:lyndsay.hughes@kcl.ac.uk)

## **Additional identifiers**

**EudraCT/CTIS number**

Nil known

**IRAS number**

325672

**ClinicalTrials.gov number**

Nil known

**Secondary identifying numbers**

CPMS 61537, IRAS 325672

# Study information

## Scientific Title

Development and pilot feasibility testing of an intervention to support immunosuppression medication adherence in kidney transplant recipients

## Study objectives

The primary aim is to assess the feasibility of a self-directed intervention to support immunosuppression medication self-management in kidney transplant recipients.

Parameters for assessing feasibility include: eligibility rates, uptake and retention rates, and acceptability from both patient and healthcare professional perspectives.

Secondary objectives include changes in self-reported adherence and targeted process variables from baseline to 6 weeks post-intervention.

## Ethics approval required

Ethics approval required

## Ethics approval(s)

Approved 31/07/2024, London - London Bridge Research Ethics Committee (2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; +44 2071048229; londonbridge.rec@hra.nhs.uk), ref: 24/LO/0496

## Study design

Interventional non-randomized

## Primary study design

Interventional

## Secondary study design

Non randomised study

## Study setting(s)

Other

## Study type(s)

Treatment

## Participant information sheet

Not available in web format, please use the contact details to request a patient information sheet

## Health condition(s) or problem(s) studied

Kidney transplant recipients

## Interventions

All participants will be allocated to the intervention arm. They will be sent the self-directed intervention booklet to work through in their own time. The psychoeducational manual aims to support kidney transplant recipients with their immunosuppression self-management through a

combination of educational and psychological components. For example, how to manage side effects, forming strategies to remember to take the medication, and gaining an understanding of how it works. A follow-up questionnaire will be sent 6 weeks post-intervention to assess changes in adherence and targeted process variables.

## **Intervention Type**

Behavioural

## **Primary outcome measure**

Feasibility will be assessed by collecting descriptive data on eligibility, recruitment and retention rates. The following will be determined:

1. Eligibility rate, recorded as the percentage of patients screened who meet the inclusion criteria
2. Uptake, recorded as the percentage of eligible patients agreeing to participate in the study by the end of recruitment
3. Retention, recorded as the percentage of participants who remain until the end of the study (i.e. complete the post-intervention questionnaire)

## **Secondary outcome measures**

Measured at baseline and 6 weeks post-intervention:

1. Medication adherence measured using the Medication Adherence Report Scale (MARS-5): overall scores as well as intentional and unintentional non-adherence sub-scale scores
2. Transplant perceptions measured using the Brief Illness Perception Questionnaire (BIPQ)
3. Medication beliefs measured using the Beliefs about Medicines Questionnaire-Specific (BMQ-Specific): necessity and concern sub-scale scores, as well as a necessity-concerns differential.
4. Psychological distress measured using the Patient Health Questionnaire Anxiety and Depression Scale (PHQ-ADS)
5. Symptom occurrence and distress measured using the Modified Transplant Symptom Occurrence and Symptom Distress Scale-59 (MTSOSD-59)
6. Self-efficacy surrounding symptom management and medication taking measured using the Theory of Planned Behaviour
7. Satisfaction with information about treatment measured using Satisfaction with Information about Medicines Scale (SIMS)
8. Quality of life measured using EQ-5D-3L

## **Overall study start date**

06/06/2021

## **Completion date**

01/02/2026

# **Eligibility**

## **Key inclusion criteria**

Phase 1 inclusion criteria:

1. 18 years of age or over
2. Living with kidney disease
3. Speak and understand English

Phase 2 patient participant inclusion criteria:

1. 18 years of age or over

2. Living with a kidney transplant
3. Prescribed immunosuppression medication.
4. Read and speak English
5. Evidence of sub-optimal immunosuppression medication adherence, i.e. a score of  $\leq 23$  on the Medication Adherence Rating Scale (MARS-5)

Phase 2 healthcare professional participant inclusion criteria:

1. The healthcare professional is a consultant nephrologist, specialist renal transplant nurse, renal pharmacist or renal psychologist working in Guy's Kidney Clinic.

### **Participant type(s)**

Patient, Health professional

### **Age group**

Adult

### **Lower age limit**

18 Years

### **Sex**

Both

### **Target number of participants**

Planned Sample Size: 80; UK Sample Size: 80

### **Key exclusion criteria**

Phase 1 exclusion criteria:

1. Currently under the care of a psychiatrist for a mental health condition
2. Insufficient command of English

Phase 2 patient participant exclusion criteria:

1. Currently under the care of a psychiatrist for a mental health condition
2. Evidence of optimal immunosuppression medication adherence on the Medication Adherence Rating Scale (MARS-5), i.e. a total score of 24 or 25
3. Insufficient command of English

### **Date of first enrolment**

01/08/2024

### **Date of final enrolment**

01/02/2025

## **Locations**

### **Countries of recruitment**

England

United Kingdom

**Study participating centre****Guys Hospital**

Guys Hospital  
Great Maze Pond  
London  
United Kingdom  
SE1 9RT

**Sponsor information****Organisation**

King's College London

**Sponsor details**

Room 8.11  
8th Floor Melbourne House  
44-46 Aldwych  
London  
England  
United Kingdom  
WC2B 4LL  
+44 (0)2078487306  
vpri@kcl.ac.uk

**Sponsor type**

University/education

**Organisation**

Guy's and St Thomas' NHS Foundation Trust

**Sponsor details**

St Thomas' Hospital  
Westminster Bridge Road  
London  
England  
United Kingdom  
SE1 7EH  
+44 (0)2071887188  
R&D@gstt.nhs.uk

**Sponsor type**

Hospital/treatment centre

# Funder(s)

## Funder type

Charity

## Funder Name

Kidney Research UK (KRUK); Grant Codes: ST\_002\_20210728

## Alternative Name(s)

## Funding Body Type

Private sector organisation

## Funding Body Subtype

Other non-profit organizations

## Location

United Kingdom

# Results and Publications

## Publication and dissemination plan

The results of the study will be reported and disseminated widely to all stakeholders through international clinical and psychological conferences, in peer-reviewed academic journals, and public and patient community events arranged with the GSTT Kidney Patient Association.

## Intention to publish date

01/10/2025

## Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study will be available upon request from the corresponding author on reasonable request. The PI (Dr Antonia Cronin, antonia.cronin@gstt.nhs.uk) will be the contact to approve and send out copies of any data. Any data shared will be de-identified. Only data from participants who have consented to their data being shared/used in future research studies will be shared.

Both qualitative and quantitative data may be requested. Data will only be shared for the purpose of research.

## IPD sharing plan summary

Available on request